Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.910
+0.040 (2.14%)
At close: Jun 26, 2026, 4:00 PM EDT
1.850
-0.060 (-3.14%)
After-hours: Jun 26, 2026, 7:06 PM EDT
Inhibikase Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Inhibikase Therapeutics stock have an average target of 5.71, with a low estimate of 4.00 and a high estimate of 8.00. The average target predicts an increase of 198.95% from the current stock price of 1.91.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Inhibikase Therapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 6 | 6 | 6 | 7 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 7 | 7 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Initiates $5 | Buy | Initiates | $5 | +161.78% | Jun 10, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates $6 | Buy | Reiterates | $6 | +214.14% | Jun 3, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $8 | Buy | Reiterates | $8 | +318.85% | May 26, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $4 | Buy | Maintains | $4 | +109.42% | May 19, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $5 | Buy | Maintains | $5 | +161.78% | May 16, 2026 |
Financial Forecast
Revenue This Year
250.00K
Revenue Next Year
333.33K
from 250.00K
Increased by 33.33%
EPS This Year
-0.37
EPS Next Year
-0.38
from -0.37
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.5M | 2.0M | |
| Avg | 250,000 | 333,330 | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | 700.0% | 32,363.6% |
| Avg | 33.3% | 8,165.9% |
| Low | -100.0% | -100.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.36 | -0.37 | |
| Avg | -0.37 | -0.38 | |
| Low | -0.38 | -0.39 |
EPS Growth
| EPS Growth | 2027 | 2028 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.